Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Boris W. Kuvshinoff"'
Autor:
Boris W. Kuvshinoff, Adrienne Groman, June S. Peng, Daniel Joyce, Steven N. Hochwald, Moshim Kukar, Kristopher Attwood, Maureen Brady
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Pasireotide was shown in a randomized trial to decrease the rate of postoperative pancreatic fistula (POPF). However, retrospective series from other centers have failed to confirm these results. METHODS Patients who underwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de24284a1b2bc6ca5cd3a059a0c71a7
https://doi.org/10.1002/jso.25949
https://doi.org/10.1002/jso.25949
Autor:
Arash Kardan, Thomas J. Giordano, Thorvardur R. Halfdanarson, Jennifer A. Chan, Lawrence S. Blaszkowsky, Christopher H. Lieu, Pamela Brock, Anthony P. Heaney, Boris W. Kuvshinoff, Satya Das, Whitney S. Goldner, Al B. Benson, Cindy Hochstetler, Beth Lynn, Heloisa P. Soares, Craig R. Sussman, Fouad Kandeel, Jin He, Daniel M. Halperin, Emily K. Bergsland, Jonathan R. Strosberg, Nataliya Uboha, Sajid A. Khan, Terence Z. Wong, Kimberly A. Miller, Michael C. Soulen, Martin J. Heslin, Venu G. Pillarisetty, Manisha H. Shah, Paxton V. Dickson, Nikolaos A. Trikalinos, Namrata Vijayvergia, Shagufta Shaheen, Diane Lauren Reidy, Sarimar N Agosto Salgado, Paul T. Fanta
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 19(7)
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paraga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c4d1f4768de00a4ab65a1b4694c30f
https://pubmed.ncbi.nlm.nih.gov/34340212
https://pubmed.ncbi.nlm.nih.gov/34340212
Autor:
Razelle Kurzrock, Shumei Kato, Boris W. Kuvshinoff, Jeffrey M. Conroy, Carl Morrison, Blake Burgher, Sarabjot Pabla, Sean T. Glenn, Mary Nesline, Felicia L. Lenzo, Paul DePietro
Publikováno v:
Ann Transl Med
Background Immunotherapeutic approaches for pancreatic ductal adenocarcinoma (PDAC) are less successful as compared to many other tumor types. In this study, comprehensive immune profiling was performed in order to identify novel, potentially actiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a299f374f12d92f9e9f0ed50d10397b
https://pubmed.ncbi.nlm.nih.gov/33569421
https://pubmed.ncbi.nlm.nih.gov/33569421
Publikováno v:
Pancreas. 47:6-11
The vast majority of patients who present with pancreatic adenocarcinoma have locally advanced or metastatic disease at the time of presentation without possibility of cure. Although in recent years there have been some new promising chemotherapy reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3707526345cc8f1535fee4e2ff43856c
https://doi.org/10.1097/mpa.0000000000000948
https://doi.org/10.1097/mpa.0000000000000948
Autor:
Steven N. Hochwald, Shipra Gandhi, Boris W. Kuvshinoff, Emmanuel Gabriel, Renuka Iyer, Kristopher Attwood
Publikováno v:
Journal of Gastrointestinal Oncology. 8:728-736
Background: Gemcitabine with capecitabine (gem-cap) is an established regimen for advanced biliary cancer (ABC) supported by our previously reported phase II trial. Here, we provide our updated experience. Methods: Single institution, retrospective s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aca3914b26374d476b1711e7fa1442a4
https://doi.org/10.21037/jgo.2017.01.24
https://doi.org/10.21037/jgo.2017.01.24
Autor:
Steven N. Hochwald, Emmanuel Gabriel, Boris W. Kuvshinoff, Steven J. Nurkin, Katherine T. Ostapoff, Kristopher Attwood
Publikováno v:
HPB. 19:587-594
Current guidelines recommend adjuvant chemotherapy for resected pancreatic adenocarcinoma (PDAC). However, no studies have addressed its survival benefit for stage I patients as they comprise10% of PDAC.Using the NCDB 2006-2012, resected PDAC patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b4476f31dad9fc339fcfa5b22545f8
https://doi.org/10.1016/j.hpb.2017.03.002
https://doi.org/10.1016/j.hpb.2017.03.002
Autor:
S.N. Akers, Jonathan Andreas, Hanchun T. DeFedericis, Mateusz Opyrchal, Peter J. Frederick, Stephen B. Edge, Patrick McKay Boland, Grace K. Dy, Sarabjot Pabla, Shashikant Lele, Paul DePietro, Marc S. Ernstoff, Sean T. Glenn, Mary Nesline, Antonios Papanicolau-Sengos, Vincent Giamo, Felicia L. Lenzo, Anne Grand'Maison, Gurkamal Chatta, Yirong Wang, Maochun Qin, Kunle Odunsi, Blake Burgher, Kazunori Kanehira, Hongbin Chen, Amy P. Early, Jeffrey M. Conroy, Boris W. Kuvshinoff, Carl Morrison, Lorenzo Galluzzi, Charles LeVea
Publikováno v:
BMC Medical Informatics and Decision Making
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-10 (2019)
Background Regulatory approval of next generation sequencing (NGS) by the FDA is advancing the use of genomic-based precision medicine for the therapeutic management of cancer as standard care. Recent FDA guidance for the classification of genomic va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e3d8b82fef46bfefd3153db751c81f
https://doi.org/10.1186/s12911-019-0743-x
https://doi.org/10.1186/s12911-019-0743-x
Autor:
Nessa Stefaniak, Boris W. Kuvshinoff, Allison Soucise, David Tear, Monica L. Murphy, Saifuddin Soniwala, Stephen B. Edge, Saby George, Mishellene McKinney, Lu Liu
Publikováno v:
Journal of Clinical Oncology. 39:e18639-e18639
e18639 Background: Clinical oncology pathways (COP) provide treatment (Rx) decision support and allow detailed quality oversight. There are limited data on use of COP and the proportion of patients receiving COP recommended Rx (concordant / “On Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3224e2b267cb34ffc1d56a0538ce5dd
https://doi.org/10.1200/jco.2021.39.15_suppl.e18639
https://doi.org/10.1200/jco.2021.39.15_suppl.e18639
Autor:
Monica L. Murphy, Amy A. Case, Mishellene McKinney, Lu Liu, Stephen B. Edge, Boris W. Kuvshinoff, Tracey O'Connor
Publikováno v:
Journal of Clinical Oncology. 38:12082-12082
12082 Background: Treating patients with metastatic cancer (MCA) requires timely integration of palliative and hospice care (PHC). The Surprise Question (SQ-“Would you be surprised if your patient died in the next year?”) may help predict short-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a26dee874b2585697e7c2a946ef2bd92
https://doi.org/10.1200/jco.2020.38.15_suppl.12082
https://doi.org/10.1200/jco.2020.38.15_suppl.12082
Autor:
Jens Hillengass, Monica L. Murphy, Nessa Stefaniak, Grace K. Dy, Stephen B. Edge, James E. Thompson, Mishellene McKinney, Boris W. Kuvshinoff, Lu Liu
Publikováno v:
Journal of Clinical Oncology. 38:7014-7014
7014 Background: Clinical oncology pathways (COP) provide decision support and benchmarking against national standards. Some organizations provide financial incentives for using COP-recommended treatment (on pathway: OnP). Treatment (Rx) other than C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dac84359d80513522376b37eae98ff4
https://doi.org/10.1200/jco.2020.38.15_suppl.7014
https://doi.org/10.1200/jco.2020.38.15_suppl.7014